Are There Risks of Genetic Mutations in Sickle Cell Patients Using Hydroxyurea?
There are potential risks of genetic mutations in patients using hydroxyurea for SCD. Although the primary benefit is to increase HbF levels, the long-term use of hydroxyurea has been associated with an increased risk of secondary cancers due to its genotoxic effects. However, the risks are often weighed against the significant benefits in symptom management and quality of life improvement for SCD patients.
